Back
ESC Professional Premium Access

Alleviation of AF related symptoms following acute conversion of recent-onset, symptomatic atrial fibrillation to sinus rhythm with flecainide acetate oral inhalation solution

Session: Novel medication strategies in atrial fibrillation
Topic: Antiarrhythmic Drug Treatment
Speaker: Professor J. Camm (London, GB)
Event: ESC Congress 2022

Congress Presentation

About the speaker

Professor John Camm

St George's University of London, London (United Kingdom of Great Britain & Northern Ireland)
76 presentations
5 followers

5 more presentations in this session

Dronedarone as early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET4 criteria

Speaker: Professor J. Piccini (Durham, US)

Access
Abstract
Slides
Thumbnail

Amiodarone and Lung Toxicity in a real-life contemporary population

Speaker: Doctor G. Tsaban (Rochester, US)

Access
Abstract
Slides
Thumbnail

Chronic amiodarone therapy and mortality among atrial fibrillation patients; insights from a real-life contemporary population

Speaker: Doctor G. Tsaban (Rochester, US)

Access
Abstract
Slides
Thumbnail

Amiodarone therapy and risk of primary lung cancer; insights from a real-life contemporary population study

Speaker: Doctor G. Tsaban (Rochester, US)

Access
Abstract
Slides
Thumbnail

Predictors of successful cardioversion of recent-onset atrial fibrillation to sinus rhythm with orally inhaled flecainide

Speaker: Doctor H. Crijns (Maastricht, NL)

Access
Abstract
Slides
Thumbnail

Access the full session

Novel medication strategies in atrial fibrillation

Speakers: Professor J. Camm, Professor J. Piccini, Doctor G. Tsaban, Doctor G. Tsaban, Doctor G. Tsaban...
Access
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb